- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06192810
Short- and Long-term Outcomes of Adrenalectomy for Primary Aldosteronism
Short- and Long-Term Outcomes of Adrenalectomy for Primary Aldosteronism in a Single UK Centre: Rear Mirror View
The proposed study is this. Short- and long-term outcomes of adrenalectomy for Primary Aldosteronism (PA) in a single centre. PA is a relatively common problem and considers as the commonest cause of secondary hypertension and can be successfully treated by adrenalectomy.
The investigators aim to gather clinical data routinely collected on participants with primary aldosteronism pre-operatively and post-operatively for a short and long term follow up.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Retrospective analysis of data from a prospectively maintained database of participants with PA who underwent surgery between 1st January 1998 and 31st December 2022 at University College London Hospital, a tertiary referral centre for endocrinology and endocrine surgery.
The clinical pathway for screening, diagnosis and stratification for adrenalectomy varied through the 24 years and was based on concurrent recommendations, published evidence, changing local expertise and best practice at the time. Throughout this period diagnosis of PA in our centre was based on the presence of hypertension and hypokalaemia, high aldosterone level, suppressed renin activity and aldosterone and renin ratio (ARR) above 850. Currently a confirmatory test (for example, saline suppression test) recommended if the aldosterone is <550pmol/L but in the upper third of the normal range or the plasma renin is non-suppressed unless the patient presents with spontaneous hypokalaemia, plasma renin below detection levels and aldosterone concentration more than 550 pmol/L.
Stratification for adrenalectomy, once a diagnosis of PA was confirmed, included cross sectional imaging of adrenals with computed tomography (CT) or magnetic resonance imaging (MRI). Adrenal venous sampling (AVS) and/or later 11C Metomidate positron emission tomography-CT (PET-CT) scan was performed if imaging showed bilateral adrenal nodules. Surgery was recommended after discussion in the multidisciplinary team meeting (endocrinologist, endocrine surgeon, biochemists and radiologist).
During the very beginning of the study laparoscopic adrenalectomy was introduced and transperitoneal lateral technique was used to perform laparoscopic adrenalectomy using 3 ports on the left and 4 ports on the right side.
Participants included in the study were characterised preoperatively by their demographics (age, sex and ethnicity) clinical presentation (blood pressure), number of antihypertensive medications and biochemical tests (potassium, aldosterone, renin, ARR ratio).
Number and type of investigations (CT, MRI, AVS, Metomidate) used to stratify for surgery and the size of the adrenal nodules on cross sectional imaging was recorded. Process of stratification was presented as lateralisation to the left or right reached as a consensus between cross sectional imaging, AVS and nuclear medicine imaging.
Data on post operative surgical outcomes included conversion rate to open adrenalectomy, postoperative complications (Clavien-Dindo)and length of hospital stay.
Postoperative outcomes were assessed within 3 months of surgery (short term) and at least 60 months (long term). Data collected were blood pressure, number of antihypertensive medications, plasma concentration of potassium, aldosterone, renin and ARR ratio. Surgical outcomes were categorised using primary aldosteronism surgical outcome score (PASO) criteria of complete, partial or absent success for both clinical and biochemical cure which reflected remission, improvement or persistence of disease.
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient underwent adrenalectomy as a management of primary aldosteronism
- Patient available for short term and long term follow up
Exclusion Criteria:
- medically treated patients
- not available for follow up
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short- and long-term assessment of clinical improvement in systolic and diastolic blood pressure
Time Frame: 3 months for short term and 5 years for long term
|
Short- and long-term clinical changes for the following parameter: -Systolic and diastolic blood pressure measured in mmHg |
3 months for short term and 5 years for long term
|
Short- and long-term assessment of clinical improvement in number of antihypertensive medications in participants
Time Frame: 3 months for short term and 5 years for long term
|
Short- and long-term clinical changes for the following parameter: -Number of antihypertensive medications |
3 months for short term and 5 years for long term
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Short- and long-term assessment of biochemical improvement in serum potassium level in participants
Time Frame: 3 months for short term and 5 years for long term
|
Short-and long-term changes in biochemical parameter: -Serum Potassium level measured in mmol/L |
3 months for short term and 5 years for long term
|
Short- and long-term assessment of biochemical improvement in serum Aldosterone level in participants
Time Frame: 3 months for short term and 5 years for long term
|
Short-and long-term changes in biochemical parameter: -Serum Aldosterone level measured in pmol/L |
3 months for short term and 5 years for long term
|
Short- and long-term assessment of biochemical improvement in serum Renin level in participants
Time Frame: 3 months for short term and 5 years for long term
|
Short-and long-term changes in biochemical parameter: -Serum Renin level measured in nmol/L |
3 months for short term and 5 years for long term
|
Short- and long-term assessment of biochemical improvement in serum Aldosterone/Renin ratio (ARR) (pmol/nmol/L) level in participants
Time Frame: 3 months for short term and 5 years for long term
|
Short-and long-term changes in biochemical parameters: -Serum Aldosterone/Renin ratio ARR (pmol/nmol/L) |
3 months for short term and 5 years for long term
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 157714
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Primary Aldosteronism
-
Radboud University Medical CenterCompletedPrimary Aldosteronism | Primary HyperaldosteronismNetherlands
-
Qifu LiWest China Hospital; Tongji Hospital; Second Affiliated Hospital, School of Medicine... and other collaboratorsRecruitingPrimary AldosteronismChina
-
Xiao ChenRecruitingPrimary AldosteronismChina
-
Liverpool University Hospitals NHS Foundation TrustRecruiting
-
The Cleveland ClinicRecruitingPrimary AldosteronismUnited States
-
University of CalgaryCanadian Institutes of Health Research (CIHR); Hypertension CanadaRecruitingPrimary AldosteronismCanada
-
AstraZenecaActive, not recruitingPrimary Aldosteronism | HyperaldosteronismUnited States
-
Chongqing Medical UniversityCompletedPrimary AldosteronismChina
-
Qifu LiThe Affiliated Hospital Of Southwest Medical UniversityCompletedPrimary AldosteronismChina
-
Chongqing Medical UniversityCompletedPrimary AldosteronismChina
Clinical Trials on Laparoscopic/open adrenalectomy
-
Suez Canal UniversityAlexandria UniversityCompletedCushing Syndrome | Pheochromocytoma | Adrenal Mass | Adrenal DiseaseEgypt
-
Zagazig UniversityCompleted
-
Zagazig UniversityCompleted
-
National Taiwan University HospitalNot yet recruitingPost Operative Pain, AcuteTaiwan
-
Chinese University of Hong KongUnknownHyperaldosteronism | Adrenocortical Adenoma | Conn SyndromeHong Kong
-
Zhe MengRecruitingPrimary Aldosteronism | Cushing Syndrome | Nonfunctional Adrenal Cortex AdenomaChina
-
National Taiwan University HospitalUnknown
-
Shoichi Fujii, MD, PhDUnknownColorectal CancerJapan
-
Samsun Liv HospitalOndokuz Mayıs UniversityCompleted
-
Cai KailinUnknownLocally Advanced Gastric CancerChina